Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Dose Range Finding Study to Evaluate the Efficacy and Safety of AZD9668 Administered Orally at Three Dose Levels to Patients With Chronic Obstructive Pulmonary Disease (COPD) on Treatment With Tiotropium

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00949975
Recruitment Status : Completed
First Posted : July 31, 2009
Results First Posted : August 3, 2012
Last Update Posted : August 3, 2012
Sponsor:
Information provided by (Responsible Party):
AstraZeneca

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The primary objective is to evaluate the dose-response relationship and efficacy of AZD9668 at 3 dose levels compared with placebo in symptomatic COPD patients by assessing effects on lung function and symptoms of COPD.

Condition or disease Intervention/treatment Phase
Chronic Obstructive Pulmonary Disease Drug: AZD9668 Drug: AZD9668 Placebo Phase 2

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 838 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Basic Science
Official Title: A 12-week, Randomised, Double-blind, Placebo-controlled, Parallel Group, Multinational, Phase IIb Dose Range Finding Study to Evaluate the Efficacy and Safety of AZD9668 Administered Orally at 3 Dose Levels to Patients With Chronic Obstructive Pulmonary Disease (COPD) on Treatment With Tiotropium
Study Start Date : July 2009
Actual Primary Completion Date : August 2010
Actual Study Completion Date : August 2010

Resource links provided by the National Library of Medicine

MedlinePlus related topics: COPD Lung Diseases

Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Active Comparator: 1
AZD9668 active treatment
 Drug: AZD9668
2 x 30 mg oral tablets twice daily (bid) for 12 weeks
Active Comparator: 2
AZD9668 active treatment
 Drug: AZD9668
2 x 10 mg oral tablets twice daily (bid) for 12 weeks
Active Comparator: 3
AZD9668 active treatment
 Drug: AZD9668
2 x 2.5 mg oral tablets twice daily (bid) for 12 weeks
Placebo Comparator: 4
AZD9668 placebo treatment
 Drug: AZD9668 Placebo
2 x Matched placebo to oral tablet twice daily (bid) for 12 weeks


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Baseline Pre-bronchodilator FEV1 (L) [ Time Frame: Day 1 ]
    Forced Expiratory Volume in 1 second (L) as a measure of lung function, measured before bronchodilator (salbutamol) use in the clinic

  2. End-value Pre-bronchodilator FEV1 (L) [ Time Frame: Measured at clinic visits: 1, 4, 8 and 12 weeks ]
    End of treatment value - week 12 for completers, otherwise Last Observation Carried forward (LOCF)


Secondary Outcome Measures :
  1. Post-bronchodilator FEV1 (L) - Baseline [ Time Frame: Day 1 ]
    Forced Expiratory Volume in 1 second (L) as a measure of lung function, measured after bronchodilator (salbutamol) use in the clinic

  2. Post-bronchodilator FEV1 (L) - End-value [ Time Frame: Measured at clinic visits: 1, 4, 8 and 12 weeks ]
    End of treatment value - week 12 for completers, otherwise Last Observation Carried forward (LOCF)

  3. Pre-bronchodilator FVC (L) - Baseline [ Time Frame: Day 1 ]
    Forced Vital Capacity (L) as a measure of lung function, measured before bronchodilator (salbutamol) use in the clinic

  4. Pre-bronchodilator FVC (L) - End-value [ Time Frame: Measured at clinic visits: 1, 4, 8 and 12 weeks ]
    End of treatment value - week 12 for completers, otherwise Last Observation Carried forward (LOCF)

  5. Post-bronchodilator FVC (L) - Baseline [ Time Frame: Day 1 ]
    Forced Vital Capacity (L) as a measure of lung function, measured after bronchodilator (salbutamol) use in the clinic

  6. Post-bronchodilator FVC (L) - End-value [ Time Frame: Measured at clinic visits: 1, 4, 8 and 12 weeks ]
    End of treatment value - week 12 for completers, otherwise Last Observation Carried forward (LOCF)

  7. Pre-bronchodilator IC (L) - Baseline [ Time Frame: Day 1 ]
    Inspiratory Capacity (L) as a measure of lung function, measured before bronchodilator (salbutamol) use in the clinic

  8. Pre-bronchodilator IC (L) - End-value [ Time Frame: Measured at clinic visits: 1, 4, 8 and 12 weeks ]
    End of treatment value - week 12 for completers, otherwise Last Observation Carried forward (LOCF)

  9. Post-bronchodilator IC (L) - Baseline [ Time Frame: Day 1 ]
    Inspiratory Capacity (L) as a measure of lung function, measured after bronchodilator (salbutamol) use in the clinic

  10. Post-bronchodilator IC (L) - End-value [ Time Frame: Measured at clinic visits: 1, 4, 8 and 12 weeks ]
    End of treatment value - week 12 for completers, otherwise Last Observation Carried forward (LOCF)

  11. PEF - Baseline Measured by Patient at Home (L/Min) in the Morning [ Time Frame: Baseline ]
    Peak Expiratory Flow (L/min) as a measure of lung function, measured at home by the patient each morning.Baseline is the mean of last 10 days of data before start of treatment

  12. PEF - End-value Measured by Patient at Home (L/Min) in the Morning [ Time Frame: Last 6 weeks on treatment ]
    Peak Expiratory Flow (L/min)

  13. FEV1 - Baseline Measured by Patient at Home (L) in the Morning [ Time Frame: Baseline ]
    Forced Expiratory Volume in 1 second (L) as a measure of lung function, measured at home by the patient each morning.Baseline is the mean of last 10 days of data before start of treatment

  14. FEV1 - End-value Measured by Patient at Home (L) in the Morning [ Time Frame: Last 6 weeks on treatment ]
    Forced Expiratory Volume in 1 second (L)

  15. EXACT - Baseline Total Score [ Time Frame: Baseline ]
    EXAcerbations of Chronic pulmonary disease Tool, patient questionnaire as a measure of respiratory symptoms (reported as units on a 0 (best health status) to 100 (worst possible status)scale). Baseline is the mean of last 10 days of data before start of treatment.

  16. EXACT - End-value Total Score [ Time Frame: Measured daily in the evening for 12 weeks ]
    EXAcerbations of Chronic pulmonary disease Tool, patient questionnaire as a measure of respiratory symptoms (reported as units on a 0 (best health status) to 100 (worst possible status)scale). Last 6 weeks on treatment.

  17. BCSS - Baseline Total Score [ Time Frame: Baseline ]
    Breathlessness, Cough and Sputum Scale, patient reported questionnaire as a measure of respiratory symptoms (reported on a 0 (best health status) to 12 (worst possible status)scale).Baseline is the mean of last 10 days of data before start of treatment

  18. BCSS - End-value Total Score [ Time Frame: Measured daily in the evening for 12 weeks ]
    Breathlessness, Cough and Sputum Scale, patient reported questionnaire as a measure of respiratory symptoms (reported on a 0(best health status) to 12(worst possible status)scale). Last 6 weeks on treatment

  19. Sputum Colour - Baseline [ Time Frame: Baseline ]
    Sputum Colour as assessed by the Bronkotest scale, reported on a scale from 1 - clear (best health status) to 5 - dark green (worst possible health status).

  20. Sputum Colour - End Value [ Time Frame: Measured at clinic visits:1, 4, 8 and 12 weeks ]
    Sputum Colour as assessed by the Bronkotest scale, reported on a scale from 1 - clear (best health status) to 5 - dark green (worst possible health status).End of treatment week 12

  21. Use of Reliever Medication [ Time Frame: Last 6 weeks on treatment ]
    Daily average of number of inhalations of reliever medication

  22. Six-minute Walk Test - Distance Walked at Baseline (m) [ Time Frame: Day 1 ]
  23. Six-minute Walk Test - End-value Distance Walked (m) [ Time Frame: Measured Day 1 and 12 weeks ]
    distance walked on vist 6 - last on treatment clinic visit

  24. St George's Respiratory Questionnaire (COPD) - Overall Score at Baseline [ Time Frame: Day 1 ]
    St George's Respiratory Questionnaire for Chronic Obstructive Pulmonary Disease, as a measure of Quality of Life (reported on a % scale from 0 (best health status) to 100(worst possible status)).

  25. St George's Respiratory Questionnaire (COPD) - End-value Overall Score [ Time Frame: Measured Day 1 and 12 weeks ]
    St George's Respiratory Questionnaire for Chronic Obstructive Pulmonary Disease, as a measure of Quality of Life (reported on a % scale from 0 (best health status) to 100(worst possible status)).questionaire assessed on vist 6 -( last on treatment clinic visit)

  26. Exacerbations - Clinic Defined [ Time Frame: Duration of the the treatment period - 12 weeks ]
    Number of patients having a clinic defined disease exacerbation


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   40 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Diagnosis of COPD with symptoms over 1 year
  • Smokers or ex-smokers
  • Males or post-menopausal females between 40 and 80 years old
  • Able to use electronic devices

Exclusion Criteria:

  • Past history or current evidence of clinically significant heart disease
  • Current diagnosis of asthma
  • Patients who require long term oxygen therapy
  • Treatment with antibiotics within 4 weeks of study visit 1b
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00949975


Locations
Show Show 105 study locations
Sponsors and Collaborators
AstraZeneca
Investigators
Layout table for investigator information
Principal Investigator: Claus Volgemeier, Dr. Director der Klinik fur Innere Medizin mit Schwerpunkt Pneumologie-Universitatsklinikum GieBen und Marburg, D-35043 Marburg, Germany
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Layout table for additonal information
Responsible Party: AstraZeneca
ClinicalTrials.gov Identifier: NCT00949975    
Other Study ID Numbers: D0520C00012
First Posted: July 31, 2009    Key Record Dates
Results First Posted: August 3, 2012
Last Update Posted: August 3, 2012
Last Verified: June 2012
Keywords provided by AstraZeneca:
Chronic
Obstructive
Pulmonary
Lung
Respiratory disease
 Efficacy
Safety and tolerability
Placebo-controlled
Pharmacokinetics
COPD
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Diseases
Lung Diseases, Obstructive
Pulmonary Disease, Chronic Obstructive
Respiratory Tract Diseases